Travere Therapeutics (NASDAQ:TVTX – Free Report) had its price target increased by Bank of America from $29.00 to $31.00 in a report issued on Tuesday,Benzinga reports. Bank of America currently has a ...

WELLESLEY HILLS, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) today announced the appointments of ...

Travere Therapeutics, Inc., today announced that the Company will present three abstracts, including one late-breaking oral presentation, at the upcoming National Kidney Foundation (NKF) Spring ...

Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announce the ...

Our kidneys take on the weighty need of filtrating virtually fifty gallons of blood on a daily basis. And, our eating habits do impose unperceived stress on these vital organs. Nowadays, the ...

Vertex Pharmaceuticals Incorporated today announced several updates on the Company's type 1 diabetes (T1D) portfolio. VX-264 Update Vertex has completed enrollment and dosing in Parts A and B of the ...

The economy has been on shaky ground for a while, and President Trump's tariffs and trade wars could finally send it into a ...

CHENGDU, China, March 26, 2025 /PRNewswire/ -- March. 25, 2025, Keymed Biosciences Inc. (HKEX: 02162) announced its annual results of 2024, along with a corporate update.

Received Clearance from the U.S. Food and Drug Administration (FDA) for Clinical Trials of Budoprutug in Primary Membranous Nephropathy (pMN), Immune Thrombocytopenia (ITP), and Systemic Lupus Erythem ...

Received Clearance from the U.S. Food and Drug Administration (FDA) for Clinical Trials of Budoprutug in Primary Membranous Nephropathy (pMN), ...

The global IgA nephropathy disease treatment market is poised for substantial growth, with projections indicating a robust CAGR of 20.8% during the forecast period from 2022 to 2028. This growth is ...

Novartis wins FDA approval for the label expansion of Fabhalta for a third indication - treatment of adults with C3 ...